Regenxbio (RGNX) Capital Expenditures (2015 - 2025)

Regenxbio's Capital Expenditures history runs 11 years deep, the most recent figure standing at -$1.0 million for Q4 2025.

• In Q4 2025, Capital Expenditures fell 194.25% year-over-year to -$1.0 million; the TTM figure through Dec 2025 stood at $889000.0 (down 63.51% YoY), while the FY2025 annual figure was $889000.0, down 63.51% from the prior year.
• Capital Expenditures was -$1.0 million for Q4 2025 at Regenxbio, down from $491000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $31.0 million in Q1 2021 to a low of -$1.0 million in Q4 2025.
• Historically, Capital Expenditures has averaged $6.4 million across 5 years, with a median of $2.0 million in 2023.
• The sharpest annual moves came in 2021 and 2025: Capital Expenditures soared 570.0% in 2021, then slumped 194.25% in 2025.
• A 5-year view of Capital Expenditures shows it stood at $14.6 million in 2021, then slumped by 62.57% to $5.5 million in 2022, then plunged by 79.41% to $1.1 million in 2023, then dropped by 4.17% to $1.1 million in 2024, then tumbled by 194.25% to -$1.0 million in 2025.
• The last three Capital Expenditures figures came in at -$1.0 million (Q4 2025), $491000.0 (Q3 2025), and $391000.0 (Q2 2025), per Business Quant data.